Smarter drug decisions,
powered by AI
Compete, accelerate, and find the best drug for your portfolio
The Vibe Bio impact
8x
Faster asset diligence
75%
SME workloads reduction
50%
More assets identified
Why Vibe Bio?
The future of drug strategy uses AI
Achieve greater agility, fresh perspectives, and sharper precision — even when expert resources are limited.
AI-powered insights, validated
Identify the full landscape to target, track changes, and triage assets with the highest potential.
Investing for cures and impact
Vibe Bio invests in founders committed to finding cures for rare and overlooked diseases.
Biopharma business development meets AI: Accelerating search & eval to find the right assets
Watch this webinar with Alok Tayi, PhD, Founder and CEO of Vibe Bio, to learn how AI is accelerating business development and helping executive teams move faster by conducting more thorough due diligence with the same resources.
Join us to discover new cures!
Contact us to learn how to streamline your due diligence drug decisions with AI or about our venture fund.
The Vibe blog
Modern biopharma BD: How to find the diamonds in the rough
Learn how top biopharma BD teams find diamonds in the rough by prioritizing strategic clarity,…
Navigating pharma strategy and portfolio prioritization: A Q&A
With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate…
Lessons from a pioneer in pharmaceutical decision-making
Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons learned from developing portfolio management and…
Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science…
Modern biopharma BD: How to find the diamonds in the rough
Learn how top biopharma BD teams find diamonds in the rough by prioritizing strategic clarity,…
Navigating pharma strategy and portfolio prioritization: A Q&A
With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate…
Lessons from a pioneer in pharmaceutical decision-making
Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons learned from developing portfolio management and…
Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science…